- Investor's Business Daily•8 hours ago
Novartis' trimming of its CAR-T program, along with a gloomy initiation report on Kite Pharma, hit investor confidence.
- Barrons.com•11 hours ago
Quoting a letter sent to 400 staffers at the drug maker, Endpoints reported today that Novartis (NVS) is disbanding its pioneering cell and gene therapy unit, and folding it into other parts of the company. As the letter penned by Usman “Oz” Aman,” the Novartis executive who over saw the high-profile unit, read, “the risk of embarking on a new adventure in uncharted territory is that things don’t always work out as envisioned.” The news is having little impact on Novartis shareholders. As Piper Jaffrey analyst Joshua Schimmer and his team wrote today: For the broader autologous CAR-T field, we struggle with the implications of Novartis' move.
- Bloomberg•13 hours ago
Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatment....
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||78.74 x 100|
|Ask||78.89 x 200|
|Day's Range||78.36 - 78.82|
|52wk Range||69.90 - 98.95|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.12|
|Avg Vol (3m)||1,454,812|
|Dividend & Yield||2.72 (3.41%)|